Lilly M&A spree: Insilico $2.75B AI + Centessa $7.8B/Metsera obesity/sleep + Orna/Ventyx deals confirmed
Key Questions
What is the value and focus of Eli Lilly's deal with Centessa?
Eli Lilly agreed to acquire Centessa for up to $7.8 billion, bullish per Cramer, focusing on NVIDIA AI, OX2R Ph2a in Q3 2026 for neuroscience, sleep, brain disorders, Parkinson's, and ADHD. This diversifies beyond GLP-1 reliance.
Details on Eli Lilly's Insilico collaboration?
The deal is $115 million upfront plus up to $2.75 billion in milestones for AI-generated drugs across 28 candidates, leveraging NVIDIA labs. It supports Eli Lilly's $1T path through AI drug development.
What are the terms of Eli Lilly's Metsera deal?
Eli Lilly's agreement with Metsera is valued at $7 billion plus $3 billion in milestones, targeting obesity and related areas. It fits the Q1 M&A spree for pipeline bolstering.
What do the Orna and Ventyx deals add to Eli Lilly?
Orna deal is $2.4 billion for circular RNA autoimmune CAR-T therapies; Ventyx focuses on inflammatories. Both enhance diversification amid obesity drug competition.
What is the AC Immune extension with Eli Lilly?
Eli Lilly paid $12.5 million (CHF 10M upfront) to expand the Morphomer Tau Alzheimer's pact, with IND-enabling studies in H1 2026 and up to >CHF 1.7B milestones. It targets oral brain-penetrant therapies.
How does Lilly's M&A spree impact its pipeline?
Q1 deals like Centessa, Insilico, Metsera, Orna, Ventyx, and AC Immune diversify into AI, neuroscience, sleep, obesity, autoimmune, and Alzheimer's, reducing GLP-1 reliance and Medicare cap risks.
What spillover effects from Lilly's Centessa deal?
Alkermes (ALKS) stock surged 15% on the Centessa buyout news, igniting hopes for sleep pipeline advancements. It highlights growing interest in orexin-based therapies.
Why is pharma M&A accelerating, including Lilly's deals?
Q1 saw giants like Lilly ramp up M&A to boost pipelines amid rebounding activity, with analysts predicting record highs. Lilly's $10B+ bets on AI and neuroscience exemplify this trend.
Q1 spree: Cramer bullish Centessa $7.8B (NVIDIA AI, OX2R Ph2a Q3 2026, neuroscience/sleep/brain/Parkinson's/ADHD); Insilico $115M+$2.75B (AI drugs/28 candidates, NVIDIA lab/$1T path); Metsera $7B+$3B; Orna $2.4B circular RNA autoimmune CAR-T; Ventyx inflammatories; AC Immune Alzheimer's pact extended + $12.5M expand Morphomer Tau/oral brain-penetrant/IND-enabling H1 2026/CHF10M upfront/>CHF1.7B milestones. Fits pipeline diversification vs GLP-1 reliance.